Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy
| Autor: | LEE MS LEE, Michael, S, Tarantini, Giuseppe, Giuseppe, Xhaxho, XHAXHO J., Jola, Yang, YANG T., Tae, Ehdaie, EHDAIE A., Ashkan, Bhatia, BHATIA R., Ravi, Favaretto, Enrico, Enrico, Tobis, TOBIS J., Jonathan |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Paclitaxel medicine.medical_treatment Myocardial Infarction Coronary Angiography Prosthesis Design Severity of Illness Index Coronary Restenosis Restenosis Internal medicine drug-eluting stent medicine Humans Transplantation Homologous Myocardial infarction Angioplasty Balloon Coronary heart transplant Aged Retrospective Studies Sirolimus Heart transplantation Chi-Square Distribution business.industry Coronary Stenosis Percutaneous coronary intervention Cardiovascular Agents Drug-Eluting Stents Thrombosis Middle Aged medicine.disease Los Angeles Treatment Outcome Italy coronary artery vasculopathy Drug-eluting stent Cardiovascular agent Conventional PCI cardiovascular system Cardiology Heart Transplantation Female business Cardiology and Cardiovascular Medicine |
| Zdroj: | Lee, MS; Tarantini, G; Xhaxho, J; Yang, T; Ehdaie, A; Bhatia, R; et al.(2010). Sirolimus-versus paclitaxel-eluting stents for the treatment of cardiac allograft vasculopathy.. JACC Cardiovasc Interv, 3(4), 378-382. doi: 10.1016/j.jcin.2010.02.005. UCLA: Retrieved from: http://www.escholarship.org/uc/item/8jv327vk |
| ISSN: | 1936-8798 |
| DOI: | 10.1016/j.jcin.2010.02.005 |
| Popis: | Objectives The aim of this study was to compare outcomes after percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in the treatment of cardiac allograft vasculopathy (CAV). Background PCI in patients with CAV is associated with increased rates of restenosis compared with PCI in patients without CAV. There are no dedicated studies on the influence of different drugeluting stents (DES) on the outcomes of patients with CAV. Methods This is a retrospective observational study of 108 consecutive patients with CAV who underwent PCI with SES and PES at UCLA Medical Center and University of Padova Medical Center between 2002 and 2008. Results Baseline characteristics were similar among SES (n 68) and PES (n 40) patients with the exception of older patients, larger minimal lumen diameter, and smaller diameter stenosis in the SES-treated patients. Angiographic follow-up at 1 year was high in the SES and PES groups (74% vs. 76%, p 0.8). The SES and PES groups had similar binary restenosis rates (10% vs. 9%, p 0.7), percent diameter stenosis (24 24% vs. 24 18%, p 0.94), and late lumen loss (0.67 1.03 mm vs. 0.68 1.11 mm, p 0.9). One-year clinical outcomes were not significantly different among CAV patients treated with either SES or PES (major adverse cardiac events: 10% vs. 15%, p 0.5; death: 3% vs. 5%, p 0.4; myocardial infarction: 3% vs. 5%, p 0.4; target vessel revascularization: 4% vs. 8%, p 0.3). Conclusions In patients who underwent PCI for CAV, both SES and PES were safe and effective with no significant differences in clinical and angiographic outcomes. Randomized clinical trials comparing different DES with longer follow-up are necessary to identify the optimal treatment strategy for patients with CAV. (J Am Coll Cardiol Intv 2010;3:378 – 82) © 2010 by the American College of Cardiology Foundation |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|